Skip to main content
. 2016 Nov 30;9:7309–7314. doi: 10.2147/OTT.S111137

Figure 1.

Figure 1

Median PFS in pivotal, COMPARZ, and the present study.

Notes: Median (range) PFS for the total population (23.0 [15–54] months), Cohort 1 (27.1 [15–46] months), and Cohort 2 (20.0 [15–54] months) in this study compared with median (95% confidence interval) PFS reported for the Pivotal study of sunitinib (11 [10–12] months)6 and the COMPARZ study (9.5 [8.3–11.1] months).13

Abbreviation: PFS, progression-free survival.